[Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].

@article{Gekht2004CosteffectEO,
  title={[Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].},
  author={A. B. Gekht and Iu B Belousov and E S Chikina and G V Serkin and Dennis Belousov and Evgeny I. Gusev},
  journal={Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova},
  year={2004},
  volume={104 10},
  pages={26-33}
}
Parkinson's disease is a neurodegenerative disorder with a growing social significance. Currently, dopamine agonists are considered as first-line medication used before levodopa treatment. High cost of dopamine agonists makes it necessary to estimate their cost efficacy by means of pharmacoeconomical studies. We studied efficacy of mirapex evaluated by… CONTINUE READING